Novo Nordisk: End to Telehealth Collaboration, Mixed Amylin Data Weigh on Valuation

Novo Nordisk (NVO) has lowered its fair value estimate to $86 from $89, driven by two key factors: the termination of its telehealth collaboration with Hims & Hers Health due to persistent compounded semaglutide competition, which reduced near-term Wegovy sales estimates, and mixed data from its amylin-targeting pipeline. Specifically, tolerability issues observed in Phase 1 for injectable amycretin led to revised sales forecasts, despite promising cagrisema data, as broader concerns remain regarding the amylin portfolio's selectivity and potential GI issues amidst looming competition from Lilly's oral orforglipron.

Analysis

Novo Nordisk's valuation is facing dual pressures from near-term revenue headwinds and long-term pipeline uncertainty, prompting a reduction in its fair value estimate to $86 from $89. The immediate concern stems from the termination of its telehealth collaboration with Hims & Hers Health, which signals that competition from compounded semaglutide continues to weigh on branded Wegovy sales more than anticipated, even following the May 22 regulatory deadline. This has directly led to a downward revision of near-term Wegovy sales estimates. Concurrently, the outlook for Novo's post-semaglutide pipeline (critical ahead of the 2032 US patent expiration) is mixed. While Phase 3 data for cagrisema is promising for a potential 2027 approval, Phase 1 tolerability issues with injectable amycretin have introduced uncertainty and reduced its sales forecast. This is compounded by a challenging competitive landscape, where Eli Lilly's oral drug orforglipron poses a significant threat due to cheaper manufacturing and simpler dosing, potentially giving it a long-term commercial edge over Novo's planned oral semaglutide launch in 2026.

Key Decisions for Investors

• Investors should closely monitor Wegovy's sales volume and pricing power in coming quarters to gauge the actual impact of persistent competition from compounded products, as this remains a key near-term risk.
• It is crucial to scrutinize upcoming clinical data from Novo's amylin pipeline, paying specific attention to the tolerability profile of amycretin and its potential for differentiation against both existing GLP-1 therapies and competitor assets.
• Consider the long-term competitive positioning against Eli Lilly, as the potential advantages of Lilly's orforglipron in cost and dosing could challenge the market share of Novo's next-generation obesity treatments.